schistosomiasis
Conditions
Interventions
Artesunate plus sulfalenepyrimethamine combined with praziquantel
Artesunate plus sulfalenepyrimethamine
Praziquantel
Sponsors
Kenya Medical Research Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Aged between 6 and 15 years old (confirmed from the date of birth recorded on the school registers), • Study participants appear healthy at enrollment, as assessed by the study clinician • Suffering from S. mansoni or S. haematobium infection • Residing in Homabay county • Able to take oral treatment, • Respective parent/ guardian gives informed consent for the child to participate in the study • Child assent to participate in study
Exclusion criteria
Exclusion criteria: • Weighing more than 50 kg, • Pregnant or lactating at the time of the study, • Presence of infection with Plasmodium falciparum or other Plasmodium spp. • Presence of severe illness, such as cerebral cysticercosis, • Signs of severe malnutrition • Hypersensitivity to Artesunates, sulfonamides or praziquantel. • Use of another anti-malaria or anti-schistosomal drug during the study, or within 28 days before the administration of the study treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy, assessed as Cure rate | — |
Secondary
| Measure | Time frame |
|---|---|
| egg reduction rate by week 6 after starting treatment;mean change in haemoglobin;Adverse events | — |
Countries
Kenya
Contacts
Public ContactErick Muok
Deputy Director
Outcome results
None listed